Supported by independent educational grants from AstraZeneca and Daiichi Sankyo.
Key Reasons to Attend:
Better understand the rationale for using ADCs, as well as their unique mechanisms of action, efficacy and safety profiles, and evolving evidence supporting their use in different solid tumors
Improve your identification of patients with different tumor types who may benefit from ADCs in clinical practice and clinical trials
Learn how to integrate HER2-, HER3-, and TROP2-targeting ADCs into treatment plans for patients with different solid tumors according to the latest evidence and expert recommendations, and effectively manage different AEs associated with these agents